NCT03281200

Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 172 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish Pulmonology Services.

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	L - Antineoplastic and immunomodulating agents	L - Antineoplastic and immunomodulating agents
DRUG	L01 - Antineoplastic agents	L01 - Antineoplastic agents
DRUG	L01X - Other antineoplastic agents	L01X - Other antineoplastic agents
DRUG	L01XE - Protein kinase inhibitors	L01XE - Protein kinase inhibitors
DRUG	L01XE31 - Nintedanib	L01XE31 - Nintedanib

Timeline

• Start date: 2017-10-24
• Primary completion: 2018-06-07
• Completion: 2018-06-07
• First posted: 2017-09-13
• Last updated: 2019-08-01
• Results posted: 2019-08-01

Locations

1 site across 1 country: Spain

Regulatory

• FDA-regulated drug study